Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

19 July 2013

Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy

Jean-François AugustoABCDEFG, Jean-François SubraACDEFG, Céline OnnoAEF, Florence VillemainAEF, Anne CroueDE, Corinne DussaussoyE, Jean PicquetE, Brigitte CoefficBE, Johnny SayeghABCDEF

DOI: 10.12659/AOT.883979

Ann Transplant 2013; 18:368-377


The long-term outcome of kidney transplant recipients on monotherapy with calcineurin inhibitors has been poorly analyzed. This study aimed to describe the long-term outcome of patients on Tac monotherapy (mTac) and to compare this regimen to a standard dual therapy with Tac/MMF.
Material and Methods
This retrospective study included 84 consecutive first kidney recipients transplanted between 1998 and 2003 and followed until 2010. Patients were treated with mTac after the 6th month of transplantation. Survival and incidence of adverse events were analyzed and compared to those of patients treated with Tac/MMF as maintenance regimen after the 6th month of transplantation.
Mean follow-up of the mTac cohort was 8.7±2.2 years. Overall patient and graft survival of the mTac cohort was 91.3% and 86.6%, respectively, at year 8 posttransplant. Tac monotherapy was started in 93.3% of patients at month 6 posttransplant and maintained in 50% of the cohort at the end of the follow-up period. Incidence of acute rejection (AR) and chronic allograft nephropathy (CAN) were 11.9% and 16.6%, respectively. Kaplan-Meyer analysis did not show any difference in patient and graft survival between mTac patients and patients under Tac/MMF. At year 6, compared to Tac/MMF patients, mTac patients had a significantly lower incidence of AR after the 6th month posttransplant and no difference in CAN, cancer, NODAT, and cardiovascular events incidence.
This work suggests that long-term maintenance immunosuppression with mTac is safe in low-immunological risk patients and should be considered for use especially in patients with MMF intolerance.

Keywords: Kidney Transplantation, Tacrolimus, long term follow-up, monotherapy

Add Comment 0 Comments

In Press

Original article  

Implementation and Evaluation of Discharge Planning for Patients Undergoing Umbilical Cord Blood Transplant...

Ann Transplant In Press; DOI: 10.12659/AOT.943770  

Original article  

Long-Term Graft and Patient Survival After Re-Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.943903  

Original article  

Post-Donation Regret and Anxiety Among Family Living Liver Donors: The Mediating Roles of Family Relationsh...

Ann Transplant In Press; DOI: 10.12659/AOT.944176  

Original article  

Effect of the Organ Donation Quality System on Donation Activity of Warsaw Hospitals

Ann Transplant In Press; DOI: 10.12659/AOT.943520  

Most Viewed Current Articles

05 Apr 2022 : Original article   12,116

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article   8,586

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article   8,504

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report   6,426

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358